Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAT8006 + BAT1308 in advanced solid tumors (phase Ib/II)
CTR20242449Phase 2Active
- Sponsor
- Bio-Thera Solutions, Ltd.
- Start
- Aug 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of BAT8006, BAT1308 in Nonhematologic neoplasms, epithelial ovarian cancer (EOC), fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), endometrial cancer (EC), sponsored by Bio-Thera Solutions, Ltd.. Started Aug 2024; status: active.
02
Drugs
BAT8006BAT1308
03
Conditions
Nonhematologic neoplasmsepithelial ovarian cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)endometrial cancer (EC)
Beyond the preview
Go deeper on CTR20242449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242449.